Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)(Tonix Pharmaceuticals)
| TNXP latest price $51.6600 (1.27%) ($47.0000 - $55.0000) on Sun. Nov. 18, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.06% (three month average) | RSI | 37 | Latest Price | $51.6600(1.27%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TNXP declines -2.4% a day on average for past five trading days. | Weekly Trend | TNXP declines -10.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TNXP advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting TNXP price | TNXP will decline at least -3.03% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.03% (StdDev 6.06%) | Hourly BBV | 0 () | Intraday Trend | -0.7% | | | |
|
1 - 5 Day Possible Target | $37.8(-26.83%) | Resistance Level | $61.57 | 5 Day Moving Average | $53.58(-3.58%) | 10 Day Moving Average | $58.48(-11.66%) | 20 Day Moving Average | $61.57(-16.1%) | To recent high | -60.3% | To recent low | 1.3% | Market Cap | $N/A | | | | Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine. |